Back To Top

You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

SYS6043 Antibody Drug Conjugate for Advanced Breast Cancer

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of SYS6043, an experimental B7-H3 targeted antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that have progressed after standard treatments or who have no standard treatment options available. You must not have received an antibody drug conjugate (ADC). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SYS6043 by IV, once every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SYS6043 is an experimental antibody drug conjugate (ADC) that uses an antibody to deliver chemotherapy directly to cancer cells with the B7-H3 protein.</li> <li class="seamTextUnorderedListItem">B7-H3 is a protein found on some cancer cells that helps them hide from the immune system.</li> <li class="seamTextUnorderedListItem">By blocking or targeting B7-H3, treatments like SYS6043 may make it easier for the immune system to recognize and attack the cancer.</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07424547' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
1

SYS6043 Antibody Drug Conjugate for Advanced Breast Cancer

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Icon

Nearest Location from 94107:
1481 miles
NEXT Oncology San Antonio
San Antonio, TX

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT07424547

Icon

Phase I

HELP GUIDE